Yunkang Group reported a RMB 2.46 million net profit for the six months ended 30 June 2026, reversing a RMB 55.36 million loss a year earlier. The turnaround was achieved even as revenue fell 19.3 % year-on-year to RMB 252.76 million, pressured by centralised procurement, price cuts and softer hospital demand.
Gross profit declined 26.5 % to RMB 78.21 million, trimming the gross margin to 30.9 % (1H25: 34.0 %). Key operating expenses were sharply reduced: selling expenses dropped 13.3 % to RMB 46.06 million, and administrative expenses fell 23.4 % to RMB 59.92 million, helped by lower share-based payment charges and tighter cost control. Net finance costs decreased 33.1 % to RMB 10.13 million after debt structure optimisation.
A RMB 44.23 million reversal of impairment losses on trade receivables—linked to successful collection of long-aged accounts—contributed materially to the swing back to profitability. Earnings per share were RMB 0.004 versus a loss per share of RMB 0.095 in the prior-year period.
Segment performance • Diagnostic testing for medical institution alliances remained the largest revenue source at RMB 157.60 million, down 12.6 % but accounting for 62.4 % of total revenue (1H25: 57.6 %). • Diagnostic outsourcing services slid 31.1 % to RMB 81.68 million amid intensified pricing pressure. • Testing services for non-medical institutions edged 6.3 % lower to RMB 13.48 million.
Balance-sheet highlights • Cash and cash equivalents stood at RMB 1.46 billion (31 Dec 2025: RMB 1.52 billion) after continued investment in a Guangzhou construction project. • Net current assets improved to RMB 894.11 million from RMB 824.13 million. • Interest-bearing borrowings declined to RMB 674.52 million; the gearing ratio was broadly stable at 59.2 %.
The board did not declare an interim dividend. Management cited ongoing optimisation of customer mix, further cost-efficiency drives and reinforced credit control as priorities amid industry price compression and evolving regulatory policies.
Comments